Analystreport

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Piper Sandler from $5.50 to $6.50. They now have an "overweight" rating on

Catalyst Pharmaceuticals, Inc.  (CPRX) 
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.catalystpharma.com